R. Roy

发表

Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial

R. Abrams, C. Hurt, J. Staffurth, 2013, The Lancet. Oncology.

Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial.

C. Hurt, D. Cunningham, J. Staffurth, 2013, The Lancet. Oncology.

Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomised controlled trial (TROG 03.01).

H. Au, J. Biagi, R. Wong, 2018, The lancet. Gastroenterology & hepatology.

CAMERA - complete assessment of elderly patients with cancer: A non-randomised feasibility study.

Miriam J. Johnson, A. Maraveyas, R. Gabe, 2019, Journal of geriatric oncology.

Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer

C. Hurt, D. Cunningham, J. Bridgewater, 2015, British Journal of Cancer.

Exploring hypoxic biology to improve radiotherapy outcomes

I. Pires, A. Beavis, R. Roy, 2022, Expert Reviews in Molecular Medicine.

PI3K inhibition as a novel therapeutic strategy for neoadjuvant chemoradiotherapy resistant oesophageal adenocarcinoma

S. Maher, I. Pires, A. Beavis, 2020, bioRxiv.

Palliative Radiotherapy in the Presence of Well-Controlled Metastatic Disease after Initial Chemotherapy May Prolong Survival in Patients with Metastatic Esophageal and Gastric Cancer

Miriam J. Johnson, A. Maraveyas, A. Beavis, 2015, Cancer research and treatment : official journal of Korean Cancer Association.

NEOSCOPE: A randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma

H. Grabsch, C. Hurt, Ricky A. Sharma, 2017, European journal of cancer.

A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO)

K. Last, M. Jones, P. Hall, 2017, British Journal of Cancer.

Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy +/− cetuximab in oesophageal cancer

C. Hurt, D. Cunningham, J. Staffurth, 2017, British Journal of Cancer.

Retention of Platinum Sensitivity till Late Stages of Tumour Progression May Imply Improved Prognosis of Oesophageal and Gastric Cancers

A. Maraveyas, M. Hingorani, S. Dixit, 2015, Oncology Research and Treatment.

Long term results and patterns of recurrence from SCOPE 1: A phase II/III randomised trial of definitive chemoradiotherapy (dCRT) plus or minus cetuximab (dCRT plus C) in esophageal cancer

C. Hurt, D. Cunningham, J. Staffurth, 2016 .

Oxaliplatin/capecitabine or carboplatin/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): Long-term results of a randomised controlled trial

H. Grabsch, Ricky A. Sharma, T. Crosby, 2021, European journal of cancer.

OC-02 Gemcitabine with or without prophylactic weight-adjusted dalteparin (WAD) in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study)

A. Maraveyas, E. Gardiner, G. Bozas, 2010 .

6503 Gemcitabine with or without prophylactic weight-adjusted dalteparin in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study)

A. Maraveyas, E. Gardiner, K. Wedgwood, 2009 .

Neo-AEGIS (Neoadjuvant trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Preliminary results of phase III RCT of CROSS versus perioperative chemotherapy (Modified MAGIC or FLOT protocol). (NCT01726452).

B. O'neill, M. Lowery, J. Reynolds, 2021 .

Neoadjuvant chemoradiotherapy for resectable oesophageal and gastro-oesophageal junction cancer--do we need another randomised trial?

A. Maraveyas, A. Bateman, M. Hingorani, 2011, Clinical oncology (Royal College of Radiologists (Great Britain)).

Development and validation of prognostic models for anal cancer outcomes using distributed learning: protocol for the international multi-centre atomCAT2 study

M. Eble, A. Dekker, D. Thwaites, 2022, Diagnostic and Prognostic Research.

Chemoradiation in pancreatic adenocarcinoma: a literature review.

A. Maraveyas, R. Roy, 2010, The oncologist.

Induction oxaliplatin capecitabine followed by switch to carboplatin-paclitaxel based RT versus continuing oxaliplatin capecitabine RT in operable esophageal adenocarcinoma: Survival analysis of the randomized phase II neoscope trial.

H. Grabsch, C. Hurt, Ricky A. Sharma, 2020 .

Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer.

A. Maraveyas, C. Ettelaie, E. Gardiner, 2012, European journal of cancer.

Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer

H. Grabsch, S. Grumett, P. Hall, 2021, JAMA oncology.

Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): The GO2 phase III trial.

H. Grabsch, S. Grumett, P. Hall, 2019, Journal of Clinical Oncology.

Reversibility of liver failure secondary to metastatic breast cancer by vinorelbine and cisplatin chemotherapy

K. O'Byrne, Ricky A. Sharma, R. Roy, 2003, Cancer Chemotherapy and Pharmacology.

Use of a non-endoscopic immunocytological device (Cytosponge™) for post chemoradiotherapy surveillance in patients with oesophageal cancer in the UK (CYTOFLOC): A multicentre feasibility study

R. Harman, R. Fitzgerald, T. Crosby, 2022, EClinicalMedicine.

Oesophageal Chemoradiotherapy in the UK--current practice and future directions.

H. Grabsch, E. Spezi, A. Bateman, 2013, Clinical oncology (Royal College of Radiologists (Great Britain)).

Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial

Jacob G. Scott, H. J. Pearson, C. Fuller, 2012 .

Reduction of interobserver variability (IOV) by FDG-PET–based tumor volume delineation (TVD) in radiotherapy planning for pancreatic cancer.

C. Hurt, T. Brunner, S. Mukherjee, 2013 .

Long-term outcome from the SCALOP trial: a multi-centre randomized phase II trial of gemcitabine or capecitabine-based chemoradiation (CRT) for locally advanced pancreatic cancer (LAPC)

R. Abrams, C. Hurt, J. Staffurth, 2016 .

Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trial

E. Spezi, K. Bradley, T. Crosby, 2023, EClinicalMedicine.

Neoadjuvant Management of Adenocarcinoma of the Esophagus and Esophagogastric Junction: Review of Randomized Evidence and Definition of Optimum Treatment Algorithm

M. Hingorani, R. Roy, G. Bozas, 2023, Oncology.

Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial

T. Hickish, M. Dobson, A. Wotherspoon, 2012, The Lancet. Oncology.

Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial

M. Lowery, G. Piessen, R. Turkington, 2023, The lancet. Gastroenterology & hepatology.

SCALOP: Results of a randomized phase II study of induction chemotherapy followed by gemcitabine (G) or capecitabine (Cap) based chemoradiation (CRT) in locally advanced pancreatic cancer (LANPC).

R. Abrams, C. Hurt, J. Staffurth, 2013 .